相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
常温,避光
- 克隆性:
单克隆
- 抗体名:
MSR1 / CD204抗体
免疫原 : Recombinant Mouse MSR1 / CD204 protein (Catalog#50129-M07H)
Reagents : PE-conjugated rabbit monoclonal antibody
Clone ID : 004
抗体宿主 : Rabbit IgG
Concentration : 5 μl/Test, 0.1 mg/ml
缓冲液 : Aqueous solution containing 0.5% BSA and 0.09% sodium azide
制备方法 : This antibody was obtained from a rabbit immunized with purified, recombinant Mouse MSR1 / CD204 (rM MSR1 / CD204; Catalog#50129-M07H; AAH03814.1; Trp 83-Val 354) and conjugated with PE under optimum conditions, the unreacted PE was removed.
MSR1 / CD204抗体 Background
Macrophage scavenger receptor types I and II, also known as Macrophage acetylated LDL receptor I and II, Scavenger receptor class A member 1, CD204, MSR1 and SCARA1, is a single-pass type II membrane protein which contains onecollagen-like domain and oneSRCR domain. Macrophages are distributed in all peripheral tissues and play a critical role in the first line of the innate immune defenses against bacterial infection by phagocytosis of bacterial pathogens through the macrophage scavenger receptor 1 (MSR1). MSR1 / SCARA1 is one of the membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis. Two types of receptor subunits exist. These receptors mediate the endocytosis of a diverse group of macromolecules, including modified low density lipoproteins (LDL). MSR1 / SCARA1 is also involved in chronic inflammation which is a risk factor for prostate cancer. MSR1 1 gene was identified as a candidate susceptibility gene for hereditary prostate cancer and as a risk factor for sporadic prostate cancer.
MSR1 / CD204抗体相关产品如下:xy-6890R CXXC5二硫键氧化还原酶锌指蛋白5抗体
xy-2996R CACNB2L-型电压依赖型钙通道β抗体
xy-2302R Catalase过氧化氢酶抗体
xy-2795R CYP2C19细胞色素P450 2C19抗体
xy-2804R Troponin T心肌特异性肌钙蛋白T抗体
xy-2807R CD161 CD161抗体
xy-15280R C7orf657号染色体开放阅读框65抗体
xy-7334R CYT 19甲基转移酶cyt-19抗体
xy-10272R CCL13单核细胞趋化蛋白4抗体
xy-8996R CD34CD34抗体
xy-7210R CD45白细胞共同抗原抗体
xy-4066R phospho-CREM (Ser271 +Ser 274)磷酸化环磷酸腺苷反应元件调节蛋白抗体
xy-4067R Connexin-37间隙连接蛋白37抗体
xy-3792R CD212型补体受体抗体
xy-3793R CD75唾液酸转移酶1/α-2,6唾液酸转移酶抗体
xy-4029R Carbonate dehydratase IX碳酸酐酶9抗体
xy-3853R CYP17细胞色素P450 17抗体
xy-2399R CYP7A1细胞色素P450 7A1抗体/胆固醇7a羟化酶
xy-5051R CYP46胆固醇24羟化酶抗体
xy-3860R CHRDL2乳腺肿瘤新因子1抗体
xy-5052R CYP7B1胆固醇25α7羟化酶抗体
xy-2369R Cytokeratin 3+12细胞角蛋白3+12抗体
xy-3755R Crkl接头蛋白CrkL抗体
xy-3899R CYP24A1细胞色素P450 24A1抗体
xy-3900R CYP2R1细胞色素P450 2R1抗体
xy-8181R COMMD10铜代谢结构域蛋白10抗体
xy-3819R CACYBP钙周期素结合蛋白抗体
xy-15281R C7orf697号染色体开放阅读框69抗体
xy-8183R COMMD3铜代谢结构域蛋白3抗体
xy-13795R C19orf7119号染色体开放阅读框71抗体
xy-8169R CBX1异染色体同源蛋白1抗体
xy-8182R COMMD8铜代谢结构域蛋白8抗体
xy-4541R Chloramphenicol氯霉素抗体
xy-13815R C4orf454号染色体开放阅读款
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验(杨希峰),Yang CY(杨春瑛) et al. Generation and characterization of monoclonal antibody against HIT3a (抗CD3单克隆抗体HIT3a的制备和特异性鉴定), Acta Academiae Medicinae Sinicae (中国医学科学院学报),1993, 15:157-162.[6] Xiong D S(熊冬生),Yang C Z(杨纯正),Shao X F(邵晓枫)et al. Generation
因为抗体的结合而减少;在人体血清中无游离的CD20存在;最重要的是B淋巴细胞瘤上的CD20少有内吞和脱落的发生[ 2-5 ] 。1997年,以CD20为靶点的嵌合抗CD20单克隆抗体Rituxan已获准应用于B细胞淋巴瘤的治疗[ 6 ]。HI47(IgG3)是我所于1990年研制成功的国内第一个抗CD20鼠源性单克窿抗体,第四届国际人类白细胞分化抗原会议将HI47命名为CD20+X[ 7 ] 。我们利用噬菌体显示技术从HI47杂交瘤细胞中克隆到抗CD20抗体HI47可变区基因,将该基因构建成为嵌合的抗
20B淋巴细胞表面的膜蛋白CD20对B淋巴细胞的增殖和分化具有调节作用[1]。由于CD20分子仅在前-B淋巴细胞、未成熟B淋巴细胞、成熟B淋巴细胞、激活B淋巴细胞中表达,而在浆细胞、淋巴多能干细胞以及其它组织均无CD20的表达[2,3,4],在人体血清中亦无游离CD20的存在[5],因此CD20可作为B淋巴细胞瘤治疗的一个理想治疗靶点。限制抗体临床使用的因素主要有抗体产生的免疫原性和抗体的生产能力是否能够满足临床需要。第四届国际人类白细胞分化抗原会议将鼠源性单克隆抗CD20抗体HI47(IgG3)正式命名为CD20+X
技术资料暂无技术资料 索取技术资料




